BETHESDA, MD, USA I May 17, 2013 I AREVA Med, an AREVA subsidiary specializing in the development of new innovative therapies to fight cancer, announced today that it will present pharmacokinetics data on the company’s ongoing Phase 1 clinical trial of its alpha radioimmunotherapy 212Pb-TCMC-Trastuzumab in patients with intra-abdominal cancers. The data will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Vancouver, June 8-12, 2013.
“We are pleased to report that the imaging dose of 212Pb-TCMC-Trastuzumab has been administered to three ovarian cancer patients with abdominal metastasis,” said Ruby Meredith, M.D., Principal Investigator at University of Alabama Birmingham. “To date, 212Pb-TCMC-Trastuzumab has been well tolerated with no serious adverse events.”
Phase 1 Clinical Trial Data
Data will be presented on three patients with HER-2- expressing ovarian cancer who had failed standard therapies. 212Pb-TCMC-Trastuzumab was administered intraperitoneally after 4mg/kg intravenous trastuzumab.
Objectives of the trial are safety, evaluation of plasma pharmacokinetics, human response, and anti-tumor effects. To date, six patients have been enrolled, and three of them have completed the six-month follow-up. After one year, the patients enter a period of long-term follow-up that includes quarterly visits for five years.
MORE ABOUT AREVA MED
AREVA Med is an AREVA subsidiary specializing in the development of innovative therapies to fight cancer. AREVA Med has developed new processes for producing high purity lead-212 ((2)(1)(2)Pb), a rare radioactive isotope that is currently at the heart of promising nuclear medicine research. In 2011, AREVA Med acquired Macrocyclics, the global leader in high performance chelating agent technology. AREVA Med is also associated with world-class scientific partners, such as the National Cancer Institute (NCI), the University of Alabama at Birmingham (UAB), and the French National Institute of Health and Medical Research (Inserm). In 2012, AREVA Med and Roche entered a strategic alliance to create novel advanced alpha radioimmunotherapy treatments to target and kill certain very aggressive types of cancer cells. For more information: http://arevamed.areva.com/ or www.targetedtrials.com.
SOURCE: Areva Med
Post Views: 160
BETHESDA, MD, USA I May 17, 2013 I AREVA Med, an AREVA subsidiary specializing in the development of new innovative therapies to fight cancer, announced today that it will present pharmacokinetics data on the company’s ongoing Phase 1 clinical trial of its alpha radioimmunotherapy 212Pb-TCMC-Trastuzumab in patients with intra-abdominal cancers. The data will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Vancouver, June 8-12, 2013.
“We are pleased to report that the imaging dose of 212Pb-TCMC-Trastuzumab has been administered to three ovarian cancer patients with abdominal metastasis,” said Ruby Meredith, M.D., Principal Investigator at University of Alabama Birmingham. “To date, 212Pb-TCMC-Trastuzumab has been well tolerated with no serious adverse events.”
Phase 1 Clinical Trial Data
Data will be presented on three patients with HER-2- expressing ovarian cancer who had failed standard therapies. 212Pb-TCMC-Trastuzumab was administered intraperitoneally after 4mg/kg intravenous trastuzumab.
Objectives of the trial are safety, evaluation of plasma pharmacokinetics, human response, and anti-tumor effects. To date, six patients have been enrolled, and three of them have completed the six-month follow-up. After one year, the patients enter a period of long-term follow-up that includes quarterly visits for five years.
MORE ABOUT AREVA MED
AREVA Med is an AREVA subsidiary specializing in the development of innovative therapies to fight cancer. AREVA Med has developed new processes for producing high purity lead-212 ((2)(1)(2)Pb), a rare radioactive isotope that is currently at the heart of promising nuclear medicine research. In 2011, AREVA Med acquired Macrocyclics, the global leader in high performance chelating agent technology. AREVA Med is also associated with world-class scientific partners, such as the National Cancer Institute (NCI), the University of Alabama at Birmingham (UAB), and the French National Institute of Health and Medical Research (Inserm). In 2012, AREVA Med and Roche entered a strategic alliance to create novel advanced alpha radioimmunotherapy treatments to target and kill certain very aggressive types of cancer cells. For more information: http://arevamed.areva.com/ or www.targetedtrials.com.
SOURCE: Areva Med
Post Views: 160
